Open AccessImpact of Organ Function–Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?
Author(s) -
Arushi Khurana,
Raphael Mwangi,
Grzegorz S. Nowakowski,
Thomas M. Habermann,
Stephen M. Ansell,
Betsy LaPlant,
Brian K. Link,
James R. Cerhan,
Mathew S. Maurer,
Thomas E. Witzig
Publication year - 2021
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.20.01935
Subject(s) - medicine , diffuse large b cell lymphoma , hazard ratio , clinical trial , lymphoma , oncology , surgery , confidence interval
Exclusion of patients needing urgent treatment or requiring novel biomarkers before enrollment has impacted the ability to enroll real-world patients in frontline trials of diffuse large B-cell lymphoma (DLBCL). The impact of baseline organ function-based eligibility criteria on this effect and clinical trial exclusion is less well-understood.